Curcumin’s modulation of androgen receptor (AR) signaling further underpins its relevance in both hormone-sensitive and castration-resistant PCa. The curcumin analog H10 selectively inhibited 17\u03b2-HSD3 activity, reducing intratumoral testosterone levels without affecting upstream enzymes [27<\/a>]. This targeted steroidogenesis inhibition translated to AR suppression and tumor growth reduction. Similarly, combined curcumin-dutasteride treatment significantly reduced PSA expression, induced DNA damage, and enhanced apoptosis, reinforcing curcumin’s potential as an adjunct to androgen deprivation therapy [14<\/a>].<\/p>\n Apoptosis induction was a consistent and potent effect observed across multiple models. Mechanistic studies revealed activation of intrinsic (Bax, caspase-3) and extrinsic (DR4\/DR5) apoptotic pathways, often coupled with mitochondrial dysfunction and ROS generation [13<\/a>, 15<\/a>, 17<\/a>]. Interestingly, in acidity-adapted PCa cells mimicking the tumor microenvironment, curcumin triggered both apoptosis and necroptosis\u2014a rare and highly cytotoxic combination\u2014via oxidative stress and ATP depletion, selectively killing cancer cells while sparing normal epithelium [15<\/a>]. Such dual-mode cell death could offer a promising strategy to overcome resistance in advanced PCa.<\/p>\n Beyond cell death, curcumin inhibited migration, invasion, and angiogenesis by modulating EMT markers (e.g., E-cadherin\u2191, ZEB1\u2193, vimentin\u2193) and angiogenic regulators (CD31\u2193) [16<\/a>, 20<\/a>]. These effects are crucial in metastatic PCa models such as PC-3 and DU145, suggesting curcumin\u2019s utility not only in tumor suppression but also in preventing disease progression.<\/p>\n However, curcumin’s poor bioavailability remains a major translational barrier [9<\/a>]. Several studies overcame this by employing nanoformulations\u2014Theracurmin, dextran-curcumin systems, scorpion venom-conjugated phytosomes, and PLGA nanoparticles\u2014each showing enhanced solubility, cellular uptake, and antitumor efficacy [11<\/a>, 13<\/a>, 16<\/a>, 22<\/a>]. Notably, PLGA nanoparticles co-loaded with curcumin and piperine inhibited steroid biosynthesis and androgen production in PCa cell lines more effectively than free curcumin [22<\/a>]. Such delivery platforms not only improve pharmacokinetics but also enable lower dosing and targeted delivery.<\/p>\n The synergistic effects of curcumin in combination therapies are another major highlight. Co-administration with chemotherapeutics (e.g., docetaxel, cisplatin), natural compounds (e.g., quercetin, carnosic acid), or physical enhancers (e.g., light irradiation) consistently amplified its anticancer potency [19<\/a>, 24<\/a>, 25<\/a>]. For instance, light-activated curcumin suppressed proliferation and integrin signaling at ultralow doses, with minimal toxicity, opening avenues for photodynamic interventions [19<\/a>]. These findings emphasize that curcumin’s full therapeutic potential may be realized when integrated into multimodal treatment regimens.<\/p>\n Mechanistically, curcumin’s interaction with emerging molecular targets adds a novel dimension to its anticancer action. Several studies reported upregulation of tumor-suppressive microRNAs (miR-30a-5p, miR-383, miR-708), leading to inhibition of key oncogenic proteins like PCLAF, LDHA, and RAP1B [17<\/a>, 31<\/a>]. Other studies demonstrated copper-mediated redox cycling and oxidative DNA damage induced by curcumin in cancer cells, offering a mechanism of selective cytotoxicity not reliant on canonical apoptotic triggers [29<\/a>]. Furthermore, modulation of energy and lipid metabolism through direct binding to PDHA1 and downregulation of lipogenic genes suggests a metabolic reprogramming role for curcumin in PCa [21<\/a>].<\/p>\n While previous reviews have addressed the anticancer effects of curcumin in general oncology, few have provided a systematic and mechanistic synthesis focused specifically on prostate cancer. Furthermore, most earlier reviews lacked critical appraisal of study quality and did not comprehensively analyze advanced delivery systems. This review is distinct in integrating molecular mechanistic insights with nanoformulation strategies, offering a more translational perspective. The inclusion of recent studies (up to March 1, 2025) ensures that the findings are current and reflective of evolving research trends.<\/p>\n
![\"figure](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/12885_2025_15152_Fig4_HTML.png\")
<\/a><\/p>\n